How much funding has X4 Pharmaceuticals raised?

X4 Pharmaceuticals has raised $446.8M in total funding, most recently a Series C round.

Who are X4 Pharmaceuticals's investors?

X4 Pharmaceuticals's investors include Coastlands Capital, Bain Capital Life Sciences, New Enterprise Associates, NEA, Polaris Partners, Altium Capital.

When was X4 Pharmaceuticals founded?

X4 Pharmaceuticals was founded in 2014.

Where is X4 Pharmaceuticals headquartered?

X4 Pharmaceuticals is headquartered in Boston, Massachusetts, United States.

What industry is X4 Pharmaceuticals in?

X4 Pharmaceuticals operates in Biotech, Drug Discovery, Healthcare, Therapeutics.

How many employees does X4 Pharmaceuticals have?

X4 Pharmaceuticals has 51-200 employees.

X4 Pharmaceuticals

IPO

With Rare Resolve.

Public · Boston, United States · Founded 2014 · $446.8M raised

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2014
Business Model: B2B
Website: x4pharma.com

Total Funding: $446.8M
Last Round: $155.3M Series COct 2025
Rounds: 7
Type: Public

About

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for rare diseases of the immune system. Its lead asset, mavorixafor (XOLREMDI®), has received U.S. FDA approval for its first indication in WHIM syndrome, with ongoing Phase 3 trials in chronic neutropenic disorders. X4 is headquartered in Boston and trades on Nasdaq under XFOR.

Summary

X4 Pharmaceuticals is a Biotech company based in Boston, United States, founded in 2014. It has raised $446.8M in total across 7 rounds, most recently a $155.3M Series C round in Oct 2025. Investors include Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates.

LinkedIn X (Twitter)